Axogen, Inc.

Axogen, Inc.

AXGNNYSE / NASDAQHealthcareSmall cap

$55.75-$0.60 (-1.1%)

Last close · Data as of Nov 20, 2026

Market cap
$2.3B
EV / EBITDA
4471.2x
Revenue
$225.2M
Net margin
-7.0%
ROCE
-4.5%

+117.2% over the last year

Axogen, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+54.1%
3M
+20.0%
6M
+30.6%
1Y
+117.2%
5Y
+471.2%

52-week range

Day change -$0.60 (-1.1%) from $56 to $56 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AXGN, bought on each weekday since 2021.

News & filings

What Axogen filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 15.7 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 35.8% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.

Read moreShow less

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Sector
Healthcare
Shares outstanding
47.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.3B
P/B
17.5x
EV / EBITDA
4471.2x
EV / Sales
10.1x
P/S
10.0x
52-week high
$58.63
52-week low
$25.67

Profitability

Operating margin
-3.5%
Net margin
-7.0%
EBITDA margin
0.2%
ROE
-12.2%
ROCE
-4.5%
ROIC
-3.9%
ROA
-7.1%
Asset turnover
1.02

Growth

Revenue
$225.2M
Revenue growth, 1Y
20.2%
Revenue CAGR, 3Y
17.6%
Net profit growth, 1Y
57.6%
Free cash flow
-$4.8M

Solvency

Current ratio
5.11
Debt / Equity
0.52
Debt / Assets
0.31
CFO / Net profit
-0.05
Cash / Market cap
1.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$225.2M
Cost of revenue$57.9M
Gross profit$167.4M
Operating expenses$175.2M
Research and development$32.9M
Selling, general and administrative$142.3M
Operating income-$7.8M
Interest and other-$7.8M
Pretax income-$15.7M
Tax and other$0.00
Net income-$15.7M

Revenue and net profit

Revenue grew 20.2% in FY2025; net profit is the dashed line.

Axogen, Inc. revenue and net profit by fiscal year
Axogen, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$138.6M-$28.9M
FY2023$159.0M-$21.7M
FY2024$187.3M-$10.0M
FY2025$225.2M-$15.7M

Cash flows

FY2025: $812.0k from operations, -$4.8M free after investment (dashed).

Axogen, Inc. operating and free cash flow by fiscal year
Axogen, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$16.1M-$37.3M
FY2023-$5.7M-$20.6M
FY2024$4.5M$11.0k
FY2025$812.0k-$4.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$225.2M+20.2%1Y
EBITDA
$507.0k-91.7%1Y
Net profit
-$15.7M
Cash from operations
$812.0k-82.1%1Y
Free cash flow
-$4.8M-43,572.7%1Y
Revenue CAGR, 3Y
17.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$225.2M$507.0k-$15.7M-$4.8M-12.2%+20.2%+57.6%

Monthly returns

Month-by-month returns of AXGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$221.7M
Liabilities$92.8M
Equity$128.8M
Paid-in capital$435.3M
Retained earnings-$307.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AXGN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Axogen, Inc. (this company)10.1x

Not shown (no positive earnings and no EV / Sales): Vera Therapeutics, Inc., Mineralys Therapeutics, Inc., Enliven Therapeutics, Inc., Kodiak Sciences Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Axogen, Inc.AXGNthis company$2.3B—17.5x-12.2%4471.2x
Vera Therapeutics, Inc.VERA$2.4B-8.0x4.0x-49.6%-7.3x
Celldex Therapeutics, Inc.CLDX$2.3B-9.1x4.5x-49.1%-8.2x
Immunome, Inc.IMNM$2.2B-10.5x3.5x-33.5%-7.1x
Mineralys Therapeutics, Inc.MLYS$2.2B-14.3x3.4x-23.9%—
Enliven Therapeutics, Inc.ELVN$2.2B-20.8x4.7x-22.6%-17.3x
BioCryst Pharmaceuticals, Inc.BCRX$2.2B8.2x-18.1x-221.4%7.2x
Kodiak Sciences Inc.KOD$2.1B—13.6x-146.1%—
Aurinia Pharmaceuticals Inc.AUPH$2.1B7.3x3.6x49.4%15.2x
Peer median—-9.1x3.8x-41.3%-7.2x

Year-to-date ROI

AXGN since 1 January, against earlier years.

Historical volatility

AXGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Axogen, Inc. operating margin by fiscal year
Axogen, Inc. operating margin by fiscal year
DateOperating margin
FY2022-21.4%
FY2023-13.5%
FY2024-1.8%
FY2025-3.5%
LineFY2025
Cost of revenueCost Of Revenue$57.9M
Gross profitGross Profit$167.3M
Operating expensesOperating Expense$175.2M
Research and developmentResearch And Development$32.9M
Total expensesTotal Expenses$233.1M
Pretax incomePretax Income-$15.7M

Learn while you research

Academy chapters picked for Axogen, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing20% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →